HK1251229A1 - 鈉通道阻斷劑 - Google Patents

鈉通道阻斷劑

Info

Publication number
HK1251229A1
HK1251229A1 HK18110615.4A HK18110615A HK1251229A1 HK 1251229 A1 HK1251229 A1 HK 1251229A1 HK 18110615 A HK18110615 A HK 18110615A HK 1251229 A1 HK1251229 A1 HK 1251229A1
Authority
HK
Hong Kong
Prior art keywords
sodium channel
channel blocker
blocker
sodium
channel
Prior art date
Application number
HK18110615.4A
Other languages
English (en)
Inventor
李炯根
金一煥
鄭名淇
金孝信
李春浩
全善娥
尹址誠
金盛榮
Original Assignee
株式會社大熊制藥
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式會社大熊制藥 filed Critical 株式會社大熊制藥
Publication of HK1251229A1 publication Critical patent/HK1251229A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
HK18110615.4A 2015-11-13 2018-08-17 鈉通道阻斷劑 HK1251229A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150159637 2015-11-13
PCT/KR2016/013029 WO2017082688A1 (ko) 2015-11-13 2016-11-11 소디움 채널 차단제

Publications (1)

Publication Number Publication Date
HK1251229A1 true HK1251229A1 (zh) 2019-01-25

Family

ID=58695815

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110615.4A HK1251229A1 (zh) 2015-11-13 2018-08-17 鈉通道阻斷劑

Country Status (30)

Country Link
US (1) US10227338B2 (zh)
EP (1) EP3375782B1 (zh)
JP (1) JP6559894B2 (zh)
KR (1) KR102245930B1 (zh)
CN (1) CN108349963B (zh)
AU (1) AU2016351526B2 (zh)
BR (1) BR112018009754B1 (zh)
CA (1) CA3003119C (zh)
CL (1) CL2018001281A1 (zh)
CO (1) CO2018005064A2 (zh)
EC (1) ECSP18038014A (zh)
ES (1) ES2821962T3 (zh)
HK (1) HK1251229A1 (zh)
HR (1) HRP20201695T1 (zh)
HU (1) HUE052569T2 (zh)
MA (1) MA43231B1 (zh)
MX (1) MX2018005940A (zh)
MY (1) MY194015A (zh)
NZ (1) NZ742069A (zh)
PE (1) PE20181301A1 (zh)
PH (1) PH12018500999A1 (zh)
PL (1) PL3375782T3 (zh)
PT (1) PT3375782T (zh)
RS (1) RS60927B1 (zh)
RU (1) RU2705578C1 (zh)
SA (1) SA518391540B1 (zh)
SG (1) SG11201803867TA (zh)
SI (1) SI3375782T1 (zh)
TN (1) TN2018000157A1 (zh)
WO (1) WO2017082688A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019114964A (ru) * 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
WO2020052509A1 (zh) * 2018-09-10 2020-03-19 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
PT1612208E (pt) * 2001-03-12 2011-10-12 Ono Pharmaceutical Co Composto de n-fenilarilsulfonamida, composição farmacêutica compreendendo o composto como ingrediente activo, intermediários de síntese para o composto e processos para a sua preparação
JP2006290791A (ja) * 2005-04-11 2006-10-26 Astellas Pharma Inc アゾール置換スルホニルベンゼン誘導体
US20090221581A1 (en) * 2005-05-25 2009-09-03 Philipp Wabnitz Methods of treating pain
US7888345B2 (en) 2006-06-09 2011-02-15 Merck Sharp & Dohme Corp. Benzaepinones as sodium channel blockers
CA2695613A1 (en) * 2006-12-19 2008-06-26 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
JP2008290791A (ja) * 2007-05-22 2008-12-04 Funai Electric Co Ltd 画像形成装置
US8124610B2 (en) * 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
PT2385938E (pt) * 2009-01-12 2015-06-02 Pfizer Ltd Derivados de sulfonamida
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
EP2788332A1 (en) 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
WO2013177224A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
US9376429B2 (en) * 2012-10-15 2016-06-28 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
US20170145003A1 (en) * 2014-02-27 2017-05-25 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel

Also Published As

Publication number Publication date
EP3375782A4 (en) 2019-05-15
MY194015A (en) 2022-11-08
HRP20201695T1 (hr) 2020-12-25
HUE052569T2 (hu) 2021-05-28
BR112018009754A8 (pt) 2019-02-26
RS60927B1 (sr) 2020-11-30
RU2705578C1 (ru) 2019-11-08
SG11201803867TA (en) 2018-06-28
JP2018533606A (ja) 2018-11-15
MA43231B1 (fr) 2020-08-31
WO2017082688A1 (ko) 2017-05-18
ES2821962T3 (es) 2021-04-28
TN2018000157A1 (en) 2019-10-04
CO2018005064A2 (es) 2018-06-20
MX2018005940A (es) 2018-08-14
KR20170056461A (ko) 2017-05-23
PT3375782T (pt) 2020-08-05
EP3375782B1 (en) 2020-07-29
CA3003119A1 (en) 2017-05-18
CA3003119C (en) 2019-10-22
SA518391540B1 (ar) 2021-04-06
SI3375782T1 (sl) 2020-10-30
CL2018001281A1 (es) 2018-08-31
BR112018009754A2 (pt) 2018-11-06
AU2016351526A1 (en) 2018-05-17
PH12018500999A1 (en) 2019-01-28
CN108349963A (zh) 2018-07-31
ECSP18038014A (es) 2018-05-31
PE20181301A1 (es) 2018-08-09
AU2016351526B2 (en) 2019-02-21
PL3375782T3 (pl) 2021-02-22
US10227338B2 (en) 2019-03-12
US20180346459A1 (en) 2018-12-06
CN108349963B (zh) 2021-03-30
JP6559894B2 (ja) 2019-08-14
BR112018009754B1 (pt) 2024-01-23
NZ742069A (en) 2019-08-30
KR102245930B1 (ko) 2021-04-29
EP3375782A1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
ZA201801308B (en) Channel access configuration
GB2568649B (en) Fitting for channel framing
EP3353938C0 (en) DESIGN OF A COMMON SYNCHRONIZATION CHANNEL FOR NARROWBAND COMMUNICATION
EP3256449A4 (en) Sodium channel blockers
HK1255832A1 (zh) 吡喃並二吡啶化合物
FI3271981T3 (fi) Tiiviste
GB201521524D0 (en) Compound
GB201522061D0 (en) Seal
ZA201804342B (en) Channel section
HK1251229A1 (zh) 鈉通道阻斷劑
GB2543741B (en) Multi channel communications
ZA201800978B (en) Baffle structure for channel
GB2536058B (en) Guide block
GB201518950D0 (en) Compound
GB201505046D0 (en) Improved glazing
GB201506030D0 (en) Seal
HK1251574A1 (zh) 四氫噁庚英吡啶化合物
GB2585157B (en) Fitting for channel framing
GB201621661D0 (en) Seal
GB201520694D0 (en) Blinds
AU2015903503A0 (en) Furring Channel
GB201522175D0 (en) Improved seal
GB201519742D0 (en) Improved leaf seal
GB201520393D0 (en) Compound
GB201520391D0 (en) Compound